Month: August 2023

HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing oil and natural gas assets, today reported financial and operating results for the three months ended June 30, 2023. SECOND QUARTER 2023 HIGHLIGHTSRecord net daily production of 1,959 barrels of oil equivalent per day (“Boe/d”), a 10% increase over second quarter of 2022 Oil production of 114,900 barrels, or 64% of total production Lease Operating Expense of $3.9 million, or $21.75 per Boe, a 17% and 24% decrease, respectively, from second quarter of 2022 Initiated share repurchase program and repurchased 163,300 shares of common stock for $0.2 million (at a weighted price of $1.48 per share)MANAGEMENT COMMENTARY Ryan Smith,...

CICERO, Ill., Aug. 14, 2023 (GLOBE NEWSWIRE) — Broadwind, Inc. (Nasdaq: BWEN, “Broadwind” or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the second quarter 2023. SECOND QUARTER 2023 RESULTS(As compared to the second quarter 2022)Revenue of $50.8 million, +0.8 million y/y Gross Profit of $8.3 million, +$5.9 million y/y GAAP Net Income of $1.4 million, +4.1 million y/y Non-GAAP Adjusted EBITDA of $5.4 million, +$5.0 million y/y Ratio of net debt to trailing twelve-month Non-GAAP Adjusted EBITDA of 2.0x as of June 30, 2023 Total backlog of $262.2 million, +$169.0 million y/y, as of June 30, 2023FULL-YEAR 2023 FINANCIAL GUIDANCEMaintaining total revenue guidance in a range of between $205 million and $220 million Increasing Adjusted...

Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and chronic pain advancing with topline data expected 3Q 2023 New respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Company previously announced results of ARTEMIS study in which OLINVYK-treated patients had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated with other IV opioids Company previously announced $3 million milestone payment from Jiangsu Nhwa Pharmaceutical; anticipates receipt of additional $15 million non-dilutive tranche from...

– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line Results on Track for Q3 2023 – – Results from Vascular Trauma Humanitarian Program in Ukraine Highlighted at 2023 Military Health System Research Symposium – – Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent corporate accomplishments. “Humacyte has made significant strides in the first half of 2023 in advancing our universally implantable Human Acellular Vessel™ (HAV) across our clinical development...

Conference call to be held today at 10:00 AM ET QUINCY, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today provided a business update and reported financial results for the three months ended June 30, 2023. Andy Shape, President and Chief Executive Officer of Stran, commented, “We continue to execute on our business growth strategies, as evidenced by an 18% year-over-year increase in revenue for the second quarter of 2023 to $17.5 million. Importantly, our organic sales increased 11% compared to the same period in the prior year. At the same time, our gross profit increased by 35% and gross profit margin...

Enrollment in PNT2002’s SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first patient dosed expected in Q1 2024 Company released its first terbium-161 preclinical data, and announced additional isotope supply partnerships for actinium-225 and lead-212 INDIANAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the second quarter ended June 30, 2023, and provided a business update. “This quarter, we began to reveal our strategy to realize one of the great opportunities presented by radioligands – the use of...

Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million milestone payment earned under the AZSTARYS® license agreement Ended Q2 2023 with $87.4 million in cash, cash equivalents, and investments, supporting our forecasted cash runway into 2026 Conference call and live audio webcast with slide presentation scheduled for today, August 14, 2023, 8:30 a.m. ET  CELEBRATION, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) —  Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today provided corporate updates and reported its financial results for the quarter ended June 30, 2023.  Recent Business and Corporate Highlights:Continued advancement of the arimoclomol...

CALGARY, Alberta, Aug. 14, 2023 (GLOBE NEWSWIRE) —  Petrus Resources Ltd. (“Petrus” or the “Company”) (TSX: PRQ) is pleased to report financial and operating results as at and for the three and six months ended June 30, 2023. Q2 2023 HIGHLIGHTS:Production up 44% – Production was up 44% from 7,280 boe/d(1) in the second quarter of 2022 to 10,492 boe/d in the second quarter of 2023 as a result of new wells brought on production in late 2022 and during the first quarter of 2023.Operating expense down 26% – Operating expense was $5.83/boe in the second quarter of 2023, a decrease of 26% from $7.92/boe in the second quarter of 2022. The decrease per boe is mainly due to higher production while holding total operating expenses relatively flat.Commodity prices decline – Realized price per boe decreased by 52% in the second quarter...

– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced its second quarter 2023 financial results and recent business highlights. Simba Gill, Ph.D., Evelo’s Chief Executive Officer, said, “We are on track for a top line read-out from our ongoing Phase 2 study in moderate psoriasis with EDP2939, our first medicine based on microbial extracellular vesicles, early in...

Increased hashrate capacity by 67% in Q2 2023 to 5.5 EH/s as of June 30, 2023. Self-mined 908 Bitcoin in Q2 2023, an increase of 70% over the Bitcoin self-mined in Q1 2023. Revenue per Bitcoin produced increased 21% in Q2 2023, while power cost per Bitcoin declined by 15%. EASTON, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) — TeraWulf Inc. (Nasdaq: WULF) (“TeraWulf” or the “Company”), which owns and operates vertically integrated, domestic Bitcoin mining facilities powered by more than 91% zero-carbon energy, today announced its unaudited financial results for the second quarter of fiscal year 2023 and provided an operational update. Second Quarter 2023 GAAP Operational and Financial HighlightsRevenue increased to $15.5 million in 2Q23 compared to $11.5 million in 1Q23. Gross profit increased to $10.3 million in 2Q23 compared to $6.5...